论文部分内容阅读
目的探讨放射性核素骨(ECT)联合肿瘤标志物检测用于老年肺癌骨转移患者的临床诊断价值。方法选取本院2010年10月~2013年10月收治的138例老年肺癌患者为研究对象,根据肺癌患者骨转移与否,分为转移组和未转移组;其中未转移组54例,转移组84例;另选88例本院同期收治的肺部良性疾病患者为对照组。分析患者的临床资料,对比分析患者ECT显像和肿瘤标志物检测结果。结果转移组:CEA为(70.1±21.0)ng/ml,CYFRA21-1为(27.2±12.3)ng/ml,NSE为(39.9±11.6)U/ml,骨显像阳性81例;未转移组:CEA为(51.3±13.7)ng/ml,CYFRA21-1为(23.2±7.1)ng/ml,NSE为(40.2±10.8)U/ml,骨显像阳性8例;对照组:CEA为(12.4±3.2)ng/ml,CYFRA21-1为(4.4±2.5)ng/ml,NSE为(12.7±1.8)U/ml,骨显像阳性8例。结论 ECT联合肿瘤标志物检测对老年肺癌患者骨转移的诊断和治疗具有重要意义。
Objective To investigate the value of combined detection of radionuclide bone (ECT) and tumor markers in the diagnosis of elderly patients with bone metastasis of lung cancer. Methods A total of 138 elderly patients with lung cancer admitted to our hospital from October 2010 to October 2013 were selected as the study subjects and divided into metastasis group and non-metastasis group according to whether bone metastasis or not in lung cancer patients. 54 cases of metastasis group, 84 cases; another 88 cases of benign lung disease patients admitted to the same period as the control group. Analysis of the clinical data of patients, comparative analysis of patients with ECT imaging and tumor marker test results. Results In the metastatic group, CEA was (70.1 ± 21.0) ng / ml, CYFRA21-1 was (27.2 ± 12.3) ng / ml, NSE was (39.9 ± 11.6) U / CEA was (51.3 ± 13.7) ng / ml, CYFRA21-1 was (23.2 ± 7.1) ng / ml, NSE was (40.2 ± 10.8) U / ml, 3.2) ng / ml, CYFRA21-1 was (4.4 ± 2.5) ng / ml, NSE was (12.7 ± 1.8) U / ml, and bone imaging positive in 8 cases. Conclusion The combination of ECT and tumor marker detection is of great significance in the diagnosis and treatment of bone metastasis in elderly patients with lung cancer.